Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

Tuesday, online health and wellness company Hims & Hers announced its intent to acquire European digital healthcare provider ...

Rising teen obesity prompts a surge in Novo Nordisk's Wegovy usage among adolescents, with prescriptions climbing 50% in 2024 ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Stocks are struggling at the start of trade as lingering trade worries stick to this market, though investors managed to shake that off on Monday. That setup could work again for Tuesday. The S&P 500 ...

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...